[DarioHealth in PR Newswire] DarioHealth Presents Three New Studies Demonstrating Improved Health in Users with Multiple Conditions at the American Diabetes Association’s 82nd Scientific Sessions

NEW YORK, June 3, 2022 /PRNewswire/ — DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today three new research studies presented at the American Diabetes Association’s (“ADA”) 82^nd Scientific Sessions being held June 3^rd to 7^th, 2022 in New Orleans, Louisiana.

Read more here.